Risk of postoperative infectious complications frommedical therapies in inflammatory bowel disease (Protocol)

Inflammatory bowel disease (IBD),which includesCrohns disease (CD) and ulcerative colitis (UC), is a chronic and incurable disorder characterized by inflammation of the gastrointestinal tract. Inflammation in UC is limited to the mucosa of the colon and rectum while Crohn's disease is associated with transmural inflammation in any portion of the gastrointestinal tract. In addition, Crohn's disease is also associated with extraintestinal manifestations in areas such as the skin, joints, and eyes. Over 1.2 million individuals have a diagnosis of IBD in North America and the worldwide prevalence of this disease is projected to increase exponentially over the next decade (Kaplan 2015). he goal of IBDtreatment is to achieve remission of clinical symptoms and resolution of gut inflammation. A plethora of pharmacological and, if necessary, surgical options are available for the treatment of IBD. Traditionally, depending on the severity of inflammation and symptoms, 5-aminosalicylates, corticosteroids, immunomodulators and biologic medications have been used. In recent years, biosimilars and smallmolecules have also been incorporated into the treatment algorithm for IBD.